Intensity-fading MALDI-TOF-MS: Novel screening for ligand binding and drug discovery

Óscar Yanes, Josep Villanueva, Enrique Querol, Francesc X. Aviles

Research output: Contribution to journalReview articleResearchpeer-review

10 Citations (Scopus)

Abstract

Ligand discovery technologies largely rely on a primary screening for molecules showing affinity to a target, coupled with an approach to identify these molecules. Matrix-assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) is attracting increasing attention as a suitable analytical technique for ligand identification owing to its high sensitivity and capacity for discrimination, its fast analysis and its ease of automation. There is now a range of related strategies for drug discovery, including a novel MS-based methodology to screen noncovalent interactions between macromolecular targets (proteases) and peptide or organic ligands (protease inhibitors) called intensity-fading (IF) MALDI-TOF-MS. © 2004 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)23-30
JournalDrug Discovery Today: TARGETS
Volume3
Issue number2 SUPPL.1
Publication statusPublished - 1 Jan 2004

Fingerprint Dive into the research topics of 'Intensity-fading MALDI-TOF-MS: Novel screening for ligand binding and drug discovery'. Together they form a unique fingerprint.

  • Cite this

    Yanes, Ó., Villanueva, J., Querol, E., & Aviles, F. X. (2004). Intensity-fading MALDI-TOF-MS: Novel screening for ligand binding and drug discovery. Drug Discovery Today: TARGETS, 3(2 SUPPL.1), 23-30.